CD44 CD44v9

CI-VAR-00000378Explore in graph →CIViC 3368

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Bladder Urothelial Carcinoma1
CD44 CD44v9	(prognostic)	Prognostic	B	Supports Poor Outcome	4	submitted	EID9397 After second line treatment with cisplatin, 64 patients with positive immunohistochemical staining of CD44v9 show a significant decrease of cancer specific survival rate (p = 0.008). In multivariate a… (full text at CIViC) PMID 29385995 · Hagiwara et al., 2018 · Open in CIViC	civic
Head and Neck Squamous Cell Carcinoma1
CD44 CD44v9	(prognostic)	Prognostic	B	Supports Poor Outcome	4	submitted	EID9396 In 72 nonchemioradioselected (N-CRS) patients the CD44v9-positive by immunohistochemistry staining group demonstrated worse disease-specific survival than the CD44v9-negative groupe (p = 0.008) after … (full text at CIViC) PMID 25751671 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.